Myelodysplastic Syndrome Excellence Forum

Conference Coverage

Analyzing Management and Treatment Options for Patients With High-Risk MDS

10/08/2024

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.

At the 2024 SOHO meeting,...

10/08/2024

Oncology

Conference Coverage

Examining Current and Upcoming Treatment Options for Patients With Low-Risk MDS

10/04/2024

Guillermo Garcia-Manero , MD;

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.

At the 2024 SOHO meeting,...

10/04/2024

Oncology

Videos

Examining Risk Stratification and Novel Treatment Options for Patients With Low and Intermediate-Risk MDS

07/28/2024

Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.

Pinkal Desai, MD, discusses risk...

07/28/2024

Oncology

Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center

Videos

How I Treat: An Elderly Patient With Lower-Risk, Ringed Sideroblastic Negative MDS

07/17/2024

Aditi Shastri, MD, discusses the treatment regimen she chose for an older patient with lower-risk, ringed sideroblastic negative myelodysplastic syndrome.

Aditi Shastri, MD, discusses the...

07/17/2024

Oncology

Areej El-Jawahri, MD, Massachusetts General Hospital

Conference Coverage

Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS

06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...

Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...

Areej El-Jawahri MD, discusses...

06/01/2024

Oncology

Conference Coverage

Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS

04/10/2024

Featuring Aditi Shastri, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...

During the 2024 Great Debates &...

04/10/2024

Oncology

Benjamin Tomlinson, MD, Seidman Cancer Center

Videos

How I Treat: A Patient With Myelodysplastic Syndrome With Isolated Deletion of 5q

02/29/2024

Benjamin Tomlinson , MD;

Benjamin Tomlinson, MD, explains the course of treatment he selected for a 49-year-old patient with myelodysplastic syndrome with isolated deletion of 5q.

Benjamin Tomlinson, MD, explains...

02/29/2024

Oncology

Videos

Luspatercept vs Epoetin Alfa for Anemia Therapy Among Patients With ESA-Naive, Transfusion-Dependent Lower-Risk MDS

10/10/2023

Guillermo Garcia-Manero , MD;

More patients achieved transfusion-independence and an increase in hemoglobin levels with luspatercept versus epoetin alfa, according to data presented at the SOHO 2023 annual meeting by Guillermo Garcia-Manero, MD.

More patients achieved...

10/10/2023

Oncology

Videos

New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS

08/19/2023

Amer Zeidan , MBBS;

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.

At the 2023 Great Debates &...

08/19/2023

Oncology

Videos

Effective Risk Stratification for Patients With Myelodysplastic Syndromes

04/26/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Amer Zeidan, MBBS, MHS, discussed effective risk stratification among patients with myelodysplastic syndromes.

At the 2023 Great Debates &...

04/26/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology